Month: June 2016

Phone Interview Research Study AL, ATTR and AA Patients
Phone interview research for patients diagnosed with Amyloid Light-Chain(AL), Transyretin (TTR), or Amyloid Protein (AA) Systemic Amyloidosis The purpose of this phone interview research study is to gather information about the symptoms and experiences of patients with Amyloid Light-Chain (AL),...
Read More
ARC Builds Bridges with Nursing Community
"Save one life and you're a hero, save one hundred lives and you're a nurse." This anonymous quote about the role of nurses in the medical profession embodies our decision to participate in the American Association of Heart Failure Nurses...
Read More
ARC Creates Pathway for Patient Engagement with FDA
Much has been said about the need to put patients at the center of drug development. The Amyloidosis Research Consortium (ARC), is doing just that. The FDA's Patient-Focused Drug Development initiative is a commitment under the fifth authorization of the...
Read More
Blazing the Trail for Amyloidosis in Brazil
Guilherme José Jucá Calheiros carried the Olympic torch in Maceio (AL) Brazil. Guilherme is diagnosed with ATTR Familial Amyloidosis (FAP), which is a rare autosomal dominant amyloidosis disease caused by the deposition of abnormal transthyretin that results from a gene mutation....
Read More

AMYLOIDOSIS RESEARCH CONSORTIUM, INC.
320 Nevada Street, Suite 210 Newton, MA 02460 USA | 617-467-5170
22 (G1) FORTH STREET, EDINBURGH, UK EH1 3LH | +44 (0) 131 550 3866
arc@arci.org

ARC is a 501(c)(3) nonprofit organization